Atom | Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

Funder: National Institutes of Health

Funding Amounts: No budget cap; up to 2 years for UG3 phase and up to 4 years for UH3 phase (max 5 years total). Budgets must reflect actual project needs.

Summary: Supports biologic-based drug discovery and development for nervous system disorders, from lead optimization through Phase I clinical trials, with NIH collaboration and access to contract research resources.

Key Information: Phased, milestone-driven cooperative agreement (UG3/UH3); limited submission; clinical trial optional; strong preclinical data required for entry.

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

Sign in to see full grant listing